The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
=== Brand names === Numorphan (suppository and injectable solution) Opana ER (extended-release tablet): June 2017 FDA removal request due to rates of IV abuse. Opana IR (immediate-release tablet) O-Morphon in Bangladesh by Ziska pharmaceutical ltd. The brand name Numorphan is derived by analogy to the Nucodan name for an oxycodone product (or vice versa) as well as Paramorphan/Paramorfan for dihydromorphine and Paracodin (dihydrocodeine). The only commercially available salt of oxymorphone in most of the world at this time is the hydrochloride, which has a free base conversion ratio of 0.891, and oxymorphone hydrochloride monohydrate has a factor of 0.85. Generic pill markings are ATV10/APO; HK10 (10 mgs) oblong white and ATV20/APO; HK20 (20 mgs) oblong white.
The coexistence of PPII and beta-turn play an important role of increasing entropy as resilin returns to its disordered form. The other function of PPII is to facilitate self-assembling process: it is found that the quasi-extended PPII is able to interact through an intermolecular reaction, and initiate the formation of fibrillar supramolecular structure.
The Accokeek Academy Capitol Heights Elementary School Glenarden Woods Elementary School Heather Hills Elementary School Highland Park Elementary School Longfields Elementary School Valley View Elementary School Greenbelt Middle School Kenmoor Middle School Walker Mill Middle School
Movat's stain is a pentachrome stain originally developed by Henry Zoltan Movat (1923–1995), a Hungarian-Canadian Pathologist in Toronto in 1955 to highlight the various constituents of connective tissue, especially cardiovascular tissue, by five colors in a single stained slide. In 1972, H. K. Russell, Jr. modified the technique so as to reduce the time for staining and to increase the consistency and reliability of the staining, creating the Russell–Movat stain.
On Czapek Yeast Extract Agar medium at 25 °C, white colonies grow in a plane, attaining a velvety to deeply floccose texture, with colony sizes that are 33–35 mm in diameter. On this medium, olive conidia are produced. The reverse of the plate can be pale or slightly tinted brown. On Malt Extract Agar medium at 25 °C, growth is rare, yet rapid when occurring, forming a velvety surface. At first, colonies are yellow-green, but ultimately turn olive due to conidial production. Colony diameter can range in size from 35 mm to 70 mm. The reverse of the plate is similar to that observed for Czapek Yeast Extract Agar medium. On 25% Glycerol Nitrate Agar at 25 °C, colony growth is planar, yet develops into a thick gel, with colony size diameter ranging from 6–12 mm. The back of the plate is described as pale or olive. At 5 °C, 25% Glycerol Nitrate Agar supports germination and a colonial growth of up to 3 mm in diameter. This species fails to grow at 37 °C. On Creatine Sucrose Agar at 25 °C, colony size diameter ranges from 4 to 10 mm. Growth is restricted, and medium pH remains around 7. No change on the back of the plate is noted. Growth on media containing orange fruit pieces for seven days at room temperature results in fruit decay, accompanied by a characteristic odour. After 14 days at room temperature, the reverse is colourless to light brown.
Sources: en.wikipedia.org
== Sources == Bartusis, Mark C. (1997). The Late Byzantine Army: Arms and Society, 1204–1453. University of Pennsylvania Press. ISBN 0-8122-1620-2. Geanakoplos, Deno John (1959). Emperor Michael Palaeologus and the West, 1258–1282: A Study in Byzantine-Latin Relations. Cambridge, Massachusetts: Harvard University Press. Nicol, Donald M. (1993) [1972]. The Last Centuries of Byzantium, 1261–1453 (Second ed.). Cambridge: Cambridge University Press. ISBN 978-0-521-43991-6. Wolff, Robert Lee (1969) [1962]. "The Latin Empire of Constantinople, 1204–1261". In Setton, Kenneth M.; Wolff, Robert Lee; Hazard, Harry W. (eds.). A History of the Crusades, Volume II: The Later Crusades, 1189–1311. Vol. 2 (Second ed.). Madison, Milwaukee, and London: University of Wisconsin Press. pp. 186–233. ISBN 0-299-04844-6.
== Structure == The active bifunctional enzyme of trypanothione synthase is found as a 74.4 KDa monomer consisting of 652 residues with two catalytic domains. Its C-terminal domain is a synthetase and has an ATP-grasp family fold that is usually found in carbon-nitrogen ligases. The N-terminal domain is a cysteine, histidine-dependent aminohydrolase amidase. Structurally the synthetase and amidase domains are bound together by three residues of Glu-650-Asp-651-Glu-652 through hydrogen bonding and salt bridge interactions with basic side chains in order for the protein to properly fold. These three residues also block the catalytic Cys-59 in the amidase domain. It is currently known that the synthetase active site is shaped in the fashion of a triangular cavity that binds the three substrates such that the end of each molecule is nestled in a vertex of the triangle. The particular residues of Arg-553 and Arg-613 have been found to key for synthetic function, however further research into the structure of trypanothione synthase must be done in order to fully understand the enzyme's active sites.
=== 2002–2005: Lilo & Stitch, The Ring, and television success === Chase's international profile expanded significantly in 2002. She was cast as the voice of Lilo Pelekai, a quirky and lonely Hawaiian girl who befriends a destructive alien fugitive, in the Walt Disney Animation Studios feature Lilo & Stitch. The film was a critical and commercial triumph, grossing over $273 million worldwide. Chase's voice performance was highly praised for its emotional authenticity and comedic timing; she was subsequently awarded the Outstanding Voice Acting in an Animated Feature at the 30th Annie Awards in 2003. She reprised the role of Lilo in the direct-to-video film Stitch! The Movie (2003) and the subsequent television series Lilo & Stitch: The Series, which aired on the Disney Channel from 2003 to 2006. Another voice acting role followed that year in Hayao Miyazaki's acclaimed animated fantasy film Spirited Away, that had a Disney-produced English-language dub where Chase provided the voice for protagonist Chihiro Ogino. Spirited Away later won the Academy Award for Best Animated Feature. Later in 2002, Chase starred as Samara Morgan in the supernatural horror film The Ring, a remake of the 1998 Japanese film Ring. Playing a malevolent, drowned child who curses a videotape, Chase required extensive prosthetic makeup and performed physically demanding stunt work in the role. Her portrayal gained wide notice in early 2000s pop culture, and the character of Samara became an iconic cinematic villain. At the 2003 MTV Movie Awards, Chase won the Best Villain award.
=== Apodization in photography === Most camera lenses contain diaphragms which decrease the amount of light coming into the camera. These are not strictly an example of apodization, since the diaphragm does not produce a smooth transition to zero intensity, nor does it shape the intensity profile beyond the "top hat" transmission of its aperture. Some lenses use other methods to reduce the amount of light let in. For example, the Minolta/Sony STF 135mm f/2.8 T4.5 lens has a special design which accomplishes this by using a concave neutral-gray-tinted lens element as an apodization filter, thereby producing a pleasant bokeh. The same optical effect can be achieved by combining depth-of-field bracketing with multiple exposure, as implemented in the Minolta Maxxum 7's STF function. In 2014, Fujifilm announced a lens utilizing a similar apodization filter in the Fujinon XF 56mm F1.2 R APD lens. In 2017, Sony introduced the E-mount full-frame lens Sony FE 100mm F2.8 STF GM OSS (SEL-100F28GM) based on the same optical Smooth Trans Focus principle. Simulation of a Gaussian laser beam input profile is also an example of apodization. Photon sieves provide a relatively easy way to achieve tailored optical apodization.
== Side effects == Side effects of dextromethorphan/bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction (including abnormal orgasm, erectile dysfunction, decreased libido, and anorgasmia), hyperhidrosis, anxiety, constipation, decreased appetite, insomnia, arthralgia, fatigue, paresthesia, and blurred vision. These side effects occurred at rates ≥2% and to a greater extent than with placebo in clinical trials.
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.